Press Releases Catalyst Pharmaceuticals, Inc.

Equities

CPRX

US14888U1016

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
15.02 ^USD	-1.18%		+2.32%	-10.65%

10/04	Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	MT
04/04	Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024	01/05	GL
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024	22/04	GL
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day	28/03	GL
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium	27/03	GL
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)	13/03	GL
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)	13/03	AQ
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference	05/03	GL
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference	05/03	AQ
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	29/02	GL
Catalyst Pharmaceuticals to Present at MDA Clinical and Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE	28/02	AQ
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE	27/02	GL
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE	27/02	AQ
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	21/02	GL
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	21/02	AQ
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024	14/02	GL
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering	10/01	GL
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock	05/01	GL
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock	05/01	GL
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma	18/12	GL
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies	05/12	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Catalyst Pharmaceuticals, Inc: Optimistic scenario

March 06, 2023 at 09:14 pm IST